Logo

Nanogen and Jurilab Partner on Type 2 Diabetes Biomarker Discovery

May 15, 2006

NEW YORK, May 15 (GenomeWeb News) - Nanogen and Jurilab will collaborate to identify and validate new prognostic markers for type 2 diabetes, the companies said today.

 

Jurilab will use data from a genetic screening project involving an isolated population in East Finland to identify potential markers associated with predisposition to diabetes as well as resistance to developing the disease.

 

The companies will collaborate to validate the diabetes associations of these markers in populations outside Finland, including case controls in Catalonia, England, Germany, and from Ashkenazi Jews.

 

Nanogen plans to develop diagnostic tests for panels of confirmed markers, and the companies will jointly seek pharmaceutical partners to develop therapeutics based on genes determined to play a role in the disease.

Breaking News
The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.